Statement of Robert K. Coughlin, President and CEO of MassBio on President Trump's Decision to End DACA
Deferred Action for Childhood Arrivals (DACA) Program Critical to Life Sciences Industry
"Our industry depends on the best and the brightest people to research and develop the next generation of breakthrough cures and treatments. President Trump’s choice to end DACA will shrink the available talent pool and threaten the growth of the life sciences industry in Massachusetts where we project close to 12,000 additional jobs over the next five years. We, at MassBio, advocate for policies that support the growth of our industry and improve patients’ lives, and therefore have asked the Massachusetts delegation to take the necessary steps to pass the DREAM Act, which would provide a permanent legislative solution and protect DACA and the “Dreamers” across the country."